BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12225434)

  • 1. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal.
    Neau-Cransac M; Morel D; Bernard PH; Merville P; Revel P; Potaux L; Saric J
    Clin Transplant; 2002 Oct; 16(5):368-73. PubMed ID: 12225434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil monotherapy in liver transplantation.
    Stewart SF; Hudson M; Talbot D; Manas D; Day CP
    Lancet; 2001 Feb; 357(9256):609-10. PubMed ID: 11558493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of renal dysfunction after orthotopic liver transplantation: options and outcomes.
    Gonwa TA
    Liver Transpl; 2003 Jul; 9(7):778-9. PubMed ID: 12827570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
    Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
    Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.
    Hong MKh; Angus PW; Jones RM; Vaughan RB; Gow PJ
    Clin Transplant; 2005 Apr; 19(2):193-8. PubMed ID: 15740554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.
    Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W
    Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil.
    Boyer O; Le Bidois J; Dechaux M; Gubler MC; Niaudet P
    Transplantation; 2005 May; 79(10):1405-10. PubMed ID: 15912111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
    Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil.
    Barkmann A; Nashan B; Schmidt HH; Böker KH; Emmanouilidis N; Rosenau J; Bahr MJ; Hoffmann MW; Manns MP; Klempnauer J; Schlitt HJ
    Transplantation; 2000 May; 69(9):1886-90. PubMed ID: 10830227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Pageaux GP; Rostaing L; Calmus Y; Duvoux C; Vanlemmens C; Hardgwissen J; Bernard PH; Barbotte E; Vercambre L; Bismuth M; Puche P; Navarro F; Larrey D
    Liver Transpl; 2006 Dec; 12(12):1755-60. PubMed ID: 17133564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
    Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].
    Lai W; Lu SC; Wang ML; Zhang J; Wu JS; Dai J; Zeng DB; Xia RP; Li N
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1529-32. PubMed ID: 19953878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
    Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
    Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
    Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2012 Mar; (3):CD008852. PubMed ID: 22419339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
    Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
    Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.